Analysts Set Vivos Therapeutics, Inc. (NASDAQ:VVOS) Price Target at $4.92

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $3.4167.

A number of research firms recently commented on VVOS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. HC Wainwright decreased their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research note on Friday.

Vivos Therapeutics Price Performance

VVOS opened at $0.97 on Thursday. Vivos Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $7.95. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The firm has a market cap of $13.14 million, a price-to-earnings ratio of -0.47 and a beta of 6.93. The company’s 50-day moving average price is $1.35 and its 200 day moving average price is $1.97.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Wednesday, April 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.08). The business had revenue of $3.82 million during the quarter, compared to analyst estimates of $7.10 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%.During the same quarter last year, the firm posted ($2.22) EPS. As a group, sell-side analysts expect that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Michael C. Skaff acquired 1,353,625 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the purchase, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Vivos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acorn Wealth Advisors LLC acquired a new position in Vivos Therapeutics in the 4th quarter worth approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Vivos Therapeutics during the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Vivos Therapeutics during the 2nd quarter valued at $220,000. DRW Securities LLC boosted its stake in shares of Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. Finally, Connective Capital Management LLC acquired a new stake in shares of Vivos Therapeutics during the 3rd quarter valued at $620,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.